Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) revealed Tuesday that the US Patent and Trademark Office granted the company a new patent for treating Autism Spectrum Disorder, characterized by challenges with social skills and speech, with cannabidiol (CBD).
The company said it received US Patent No 10,314,792, titled “Treatment of Autism Spectrum Disorder with Cannabidiol,” which includes claims linked to methods of treating Autism Spectrum Disorder by administering a therapeutically effective amount of synthetic CBD.
The new patent, which expires in 2038, is part of an expanding intellectual property portfolio covering the Devon, Pennsylvania-based company’s Zygel, a CBD gel.
Zygel was earlier referred to as ZYN002, a synthetic cannabidiol formulated as a permeation-enhanced gel for skin delivery.
The new patent arrives as enrollment speeds up in Zynerba’s open label Phase 2 BRIGHT study evaluating the safety, tolerability and potency of Zygel for treating children and adolescents with Autism Spectrum Disorder. The company expects to report top line data in the first half of 2020.
Zynerba already has a patent (No 10,213,390) for claims linked to methods of treating Fragile X Syndrome by administering an effective dose of synthetic or purified CBD.
The US Food and Drug Administration earlier granted fast track designation to Zygel to expedite the development of the drug to treat Fragile X syndrome in children and young adults suffering from this common form of inherited learning disability and attention deficit disorder.
Enrollment is progressing in a pivotal CONNECT-FX Trial of Zygel in Fragile X syndrome, the company said in a statement with “data expected in the second half of 2019.”
Contact Uttara Choudhury at [email protected]